Figure 1.
The US-expectancy of the CS+ and CS− trials during acquisition (A1–A8) and retrieval-extinction (E1–E12) for the devaluation and control groups.
Figure 2.
Mean skin conductance response.
The SCR of the CS+ and CS− trials during acquisition (A1–A8) and retrieval-extinction (E1–E12) for the devaluation and control groups.
Figure 3.
Post-acquisition, post-revaluation, and post-extinction for the devaluation and control groups.